IBRX
IMMUNITYBIO INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
IMMUNITYBIO INC (IBRX) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$60.59M; the largest are Izzy Englander, Renaissance Technologies, Joel Greenblatt. 3 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 2 added, 1 trimmed, 1 closed. 1 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders43 also report options
Congress trades1
Price$8.83vs quarter-end+0.86%
Sectors0
This quarter's moves
Top holderNew1
Added2
Trimmed / sold2
Izzy EnglanderCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $33.59M— of portfolio3,836,9002026 Q2
Value $14.90M— of portfolio1,701,7002026 Q2
Value $1.99M— of portfolio227,5002026 Q2
Value $1.16M— of portfolio132,0002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $33.59M | — | — |
| Ken GriffinPUT | $14.90M | — | — |
| Paul Tudor JonesCALL | $1.99M | — | — |
| Steven CohenCALL | $1.16M | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.